Hepatic Safety of High-Dose Rifampicin for Tuberculosis Treatment in TB/HIV Co-infected Patients: A Randomized Clinical Trial
Sekossounon Sanni, Ablo Prudence Wachinou, Corinne Simone Colette Merle, Kossi Wilfried Bekou, Marius Esse, Severin Gossa, Khalil Gomina, Lamine Baba‐Moussa, et al. (9 authors)
Archives of Pharmacy Practice · 2021-01
Abstract
High-dose Rifampicin regimens have been shown to be more effective for tuberculosis (TB) treatment in TB/HIV co-infected patients. This study assessed the hepatic safety of a high-dose Rifampicin regimen among TB/HIV co-infected patients. 811 TB/HIV co-infected patients, antiretroviral treatment (ART) naïve, at least 18 years old with a CD4 T-cell count between 50 and 350 cells/mm3 were enrolled. Patients with multidrug-resistant tuberculosis were excluded. Patients had received first-line
MeSH terms
- Rifampicin
- Medicine
- Human immunodeficiency virus (HIV)
- Tuberculosis
- Randomized controlled trial
- Clinical trial
- Tb treatment
- Internal medicine
- Pharmacology
- Virology